Chinese investigators have reported that high levels of triggering receptor expressed on myeloid cells 2 (TREM2) expression, which are immunosuppressive in multiple solid tumors, were protective in glioblastoma multiforme (GBM). The findings were published May 23, 2024, in Cancer Cell. Read More
Lung adenocarcinoma (LUAD) is a subtype of non-small-cell lung cancer (NSCLC) that represents around 40% of all lung tumors. Despite therapeutic advancements, LUAD remains a leading cause of cancer-related death worldwide. Previous research found that ferredoxin-1 (FDX1) dysregulation plays a role in LUAD progression. FDX1 is a crucial regulator of copper homeostasis and cuproptosis, a regulated form of cell death triggered by excessive copper levels. Read More
Tetra Pharm Technologies ApS and Kvanctify ApS have entered into a strategic partnership to accelerate the identification and development of novel drug candidates targeting the endocannabinoid system. Read More
The maintenance of mitochondrial homeostasis plays a crucial role in tumor cell survival and growth. Mitochondrial integrity is regulated by proteins in the mitochondrial inner membrane, such as prohibitin (PHB). PHB has been found overexpressed in several cancer types and contributes to tumorigenesis. Read More
Alternative splicing is known to play an important role in tissue development. Scientists at Brigham and Women’s Hospital have looked into the association between a chronic obstructive pulmonary disease (COPD) genetic variant and cell-specific splicing of putative ciliary rootlet coiled-coil protein-like 1 protein (CROCCP2). Read More
Netherton syndrome (NS) is a rare genetic disease caused by loss of functional lympho-epithelial Kazal-type-related inhibitor (LEKTI, SPINK5). It was hypothesized that small-molecule inhibitors of KLK5 could replace deficient LEKTI in NS. Read More
Full-Life Technologies Ltd. has received IND clearance by the FDA, allowing it to conduct clinical trials of 225Ac-FL-020, its PSMA-targeted radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer. Read More
Beta Pharma Inc. has presented 1,5-naphthyridine derivatives acting as GTPase KRAS (G12D mutant) and/or (G12C mutant) inhibitors and thus reported to be useful for the treatment of cancer. Read More
Georgiamune Inc. has gained FDA clearance for its IND application for GIM-531, a first-in-class oral regulatory T cell (Treg) inhibitor that enables the restoration of a strong immune response against cancer. Read More
Insilico Medicine Inc. has identified NLRP3 inflammasome inhibitors reported to be useful for the treatment of autoimmune and inflammatory disorders. Read More
Researchers from Shanghai Jiao Tong University presented findings from a study that aimed to assess the metabolic landscape of intestinal fibrosis in Crohn’s disease. Read More
Programmed cell death protein 1 (PD-1) is among the immune checkpoint molecules better explored in immunotherapy for cancer. However, it is necessary to obtain novel therapies where preclinical efficacy and safety data could translate into enhanced predictability of human efficacy, pharmacokinetics and side effects. Read More
Biosplice Therapeutics Inc. has disclosed dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) inhibitors reported to be useful for the treatment of cancer, diabetes and Alzheimer’s disease. Read More
KRAS is a GTPase that switches from an active GTP-bound conformation and an inactive GDP-bound conformation. Recently, several covalent KRAS G12C inhibitors that stick the protein in its GDP-bound inactive state have reached the clinic. However, the clinical benefit to date is limited and there is a need for next-generation compounds with better target engagement. Read More
Leyden Laboratories BV has patented polypeptides acting as spike glycoprotein (S) (SARS-CoV-2; COVID-19 virus) ligands reported to be useful for the treatment of SARS-CoV-2 infections. Read More
